The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

May 12 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Sunday its drug Zepbound was superior to Novo Nordisk's (NOVOb.CO), opens new tab Wegovy across five weight-loss targets such as ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in the ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly's pill works in a similar way to Wegovy, Ozempic, and Novo Nordisk's diabetes pill Rybelsus, targeting a gut hormone called GLP-1 to suppress a person's appetite and regulate blood sugar.

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Hims & Hers has been expanding its presence in the weight management market, with its existing Novo partnership representing ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.